Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06221969 · ClinicalTrials.gov registry record · Phase 3
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
A Phase 3 study of Type 2 Diabetes, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT06221969 is a Phase 3 study of Type 2 Diabetes that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 1,000 participants, roughly in line with the 1,099-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target. The trial reports 20 study locations across 4 states.
The verdict
NCT06221969, a Phase 3 study of Type 2 Diabetes, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.
Conditions Studied
Interventions
- DRUG Tirzepatide
- DRUG Semaglutide
- DRUG Cagrilintide
Study Locations (20)
California
- Velocity Clin Res-Chula Vista - Chula Vista
- Headlands Research California, LLC - Escondido
- Neighborhood Healthcare - Escondido
- St. Jude Heritage Yorba Linda - Pediatric Ste D - Fullerton
- Diabetes & Endocrine Specialists - La Mesa - La Mesa
- Diabetes and Endocrine Specialists - La Mesa - La Mesa
- Velocity Clin Res San Diego - La Mesa
- Clinical Trials Research - Lincoln
- Loma Linda Univ Hlth Cr Endo - Loma Linda
- Valley Clinical Trials, Inc. - Northridge
- Desert Oasis Healthcare - Palm Springs
- Velocity Clin Res - Panorama - Panorama City
- Western University of Health Sciences - Pomona
Arizona
- Prime Medical Group, LLC - Gilbert
- Velocity Clinical Research-Phoenix - Phoenix
- Synexus Rsch /Cnt Phnx Med C - Phoenix
Alabama
- Synexus Clin Res-Birmingham - Birmingham
- Univ of Alabama_Birmingham - Birmingham
Arkansas
- Arkansas Clinical Research - Little Rock
- Unity Health-Searcy Medical Center - Searcy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2024-01-16 |
| Est. Completion | 2026-04-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06221969
The ClinicalTrials.gov registry entry for NCT06221969 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,099-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 3 interventions - of which Tirzepatide is the first listed.
NCT06221969 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT06221969 about?
NCT06221969 is a clinical study titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor". This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some c...
What is the current status of trial NCT06221969?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2024-01-16. Estimated completion is 2026-04-03.
What conditions does trial NCT06221969 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT06221969?
The interventions under investigation include: Tirzepatide (DRUG), Semaglutide (DRUG), Cagrilintide (DRUG).
Who is sponsoring clinical trial NCT06221969?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06221969 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.